Withings ScanWatch

Withings, a French consumer-health-electronics company founded in 2008 and independent again since 2018 after being bought back from Nokia, makes the ScanWatch line of biometric-primary hybrid analog smartwatches with cardiac and respiratory AI augmentation, recorded in the new biometric form factor. The ScanWatch 2 and ScanWatch Nova pair an analog dial with optical heart-rate, electrical ECG, blood-oxygen, and continuous temperature sensors on roughly a 30-day battery. Their FDA clearances are the ECG app, cleared in October 2021 to classify atrial fibrillation, sinus rhythm, and high heart rate for adults 22 and older, updated in July 2025 so that the ScanWatch 2 ECG is cleared over the counter, no longer requiring a board-certified cardiologist to activate, with a new eight-classification atrial-fibrillation algorithm, plus a cleared blood-oxygen feature that supports tracking breathing disturbances at night. A cap-flag applies because the breathing-disturbance detection is a screening aid rather than a sleep-apnea diagnosis, and framing it as diagnosis exceeds scope. Withings offers a clean contrast to Apple, since its blood-oxygen and ECG features were never disabled in the US as it is not party to the Masimo dispute, and the notable 2025 regulatory event was a positive over-the-counter liberalization rather than a restriction. It sells by hardware purchase with an optional Withings+ membership, its clinical-validation posture is substantial for its size with strong study framing and CE medical marking, and the exact clearance numbers and dates for the ScanWatch 2 blood-oxygen and temperature features and the standard US list prices are approximate and not fully verified.

Withings ScanWatch is listed at $370 on the DEPLOY registry. This is an actual sale price on record.

Yes. Withings ScanWatch is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Withings ScanWatch's recorded specifications on the DEPLOY registry: Battery: 35 days; Weight: 0.053 kg. See the Specs section for the full sourced set.

Withings ScanWatch is made by Withings, based in Issy-les-Moulineaux, France, founded in 2008.

1 verified deployment of Withings ScanWatch is on the DEPLOY registry, including at Global.

Withings ScanWatch is available for purchase - a real sale price is on record (see the pricing section for the figure and its source).

Withings ScanWatch has 2 regulatory records on the DEPLOY registry: FDA 510(k) clearance (K201456), cleared; FDA 510(k) clearance (K201456), cleared. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable biometric robots to Withings ScanWatch include Blackrock Neuroport Array, BrainQ Non-Invasive BCI, Neko Body Scan, RNS System.

Withings ScanWatch and Blackrock Neuroport Array (Blackrock Neurotech · 5 deployments) are both biometric robots on the DEPLOY registry. Withings ScanWatch has 1 verified deployment on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Withings ScanWatch ranks in roughly the top 81% of biometric models tracked by the registry.

Withings ScanWatch is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Withings ScanWatch has 1 active incident on record in the DEPLOY registry. 1 recall on record (1 moderate). Most recent: Dec 2022. Retracted incidents are excluded from this count.

Yes. Withings received FDA clearance for the ScanWatch ECG and SpO2 monitoring features. The ScanWatch 2 offers on-demand SpO2 tracking, measuring blood oxygen levels in 30 seconds from the wrist. This can help detect respiratory disorders like COPD. Withings has 510(k) K201456.